Vitrolife AB (publ) becomes lead investor in AutoIVF
Vitrolife Group (VTRLY) has announced a strategic investment in AutoIVF, becoming its lead investor. AutoIVF is developing 翱惫补搁别补诲测鈩�, an automated system that streamlines egg retrieval and preparation in IVF procedures. The technology aims to enhance fertility services and enable egg retrieval outside traditional IVF lab settings.
This investment aligns with Vitrolife's strategy to develop an end-to-end platform connecting products and services across the IVF workflow. The financial impact is described as minimal, with more details to be disclosed during Q2 earnings. The partnership aims to accelerate AutoIVF's path to market and expand access to fertility care through automation and innovation.
Vitrolife Group (VTRLY) ha annunciato un investimento strategico in AutoIVF, diventandone il principale investitore. AutoIVF sta sviluppando 翱惫补搁别补诲测鈩�, un sistema automatizzato che ottimizza la raccolta e la preparazione degli ovociti nelle procedure di fecondazione in vitro (FIV). Questa tecnologia mira a migliorare i servizi di fertilit脿 e a permettere la raccolta degli ovociti al di fuori dei laboratori tradizionali di FIV.
Questo investimento 猫 in linea con la strategia di Vitrolife di creare una piattaforma integrata che collega prodotti e servizi lungo l鈥檌ntero processo della FIV. L鈥檌mpatto finanziario 猫 descritto come minimo, con maggiori dettagli che saranno comunicati durante la presentazione dei risultati del secondo trimestre. La partnership punta ad accelerare l鈥檌ngresso di AutoIVF sul mercato e a estendere l鈥檃ccesso alle cure per la fertilit脿 attraverso l鈥檃utomazione e l鈥檌nnovazione.
Vitrolife Group (VTRLY) ha anunciado una inversi贸n estrat茅gica en AutoIVF, convirti茅ndose en su principal inversor. AutoIVF est谩 desarrollando 翱惫补搁别补诲测鈩�, un sistema automatizado que optimiza la extracci贸n y preparaci贸n de 贸vulos en procedimientos de fertilizaci贸n in vitro (FIV). Esta tecnolog铆a busca mejorar los servicios de fertilidad y permitir la extracci贸n de 贸vulos fuera de los laboratorios tradicionales de FIV.
Esta inversi贸n se alinea con la estrategia de Vitrolife de desarrollar una plataforma integral que conecte productos y servicios a lo largo del proceso de FIV. El impacto financiero se describe como m铆nimo, y se proporcionar谩n m谩s detalles durante los resultados del segundo trimestre. La asociaci贸n tiene como objetivo acelerar la entrada de AutoIVF al mercado y ampliar el acceso a la atenci贸n de fertilidad mediante la automatizaci贸n y la innovaci贸n.
Vitrolife Group (VTRLY)臧赌 AutoIVF鞐� 鞝勲灥鞝� 韴瀽毳� 氚滍憸頃橂┌ 欤检殧 韴瀽鞛愱岸� 霅橃棃鞀惦媹雼�. AutoIVF電� IVF 鞁滌垹鞐愳劀 雮滌瀽 毂勳法 氚� 欷�牍� 瓿检爼鞚� 鞛愲彊頇旐晿電� 翱惫补搁别补诲测鈩� 鞁滌姢韰滌潉 臧滊皽 欷戩瀰雼堧嫟. 鞚� 旮办垹鞚� 靸濎嫕 靹滊箘鞀れ潣 須湪靹膘潉 雴掛澊瓿� 鞝勴喌鞝侅澑 IVF 鞁ろ棙鞁� 鞕鸽秬鞐愳劀霃� 雮滌瀽 毂勳法臧赌 臧赌電ロ晿霃勲 頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
鞚措矆 韴瀽電� IVF 鞝� 瓿检爼鞐� 瓯胳硱 鞝滍拡瓿� 靹滊箘鞀るゼ 鞐瓣舶頃橂姅 韱淀暕 頂岆灚韽� 臧滊皽鞚措澕電� Vitrolife鞚� 鞝勲灥瓿� 攵�頃╉暕雼堧嫟. 鞛鞝� 鞓來枼鞚� 氙鸽頃橂┌, 2攵勱赴 鞁れ爜 氚滍憸 鞁� 於旉岸� 靹鸽秬 鞝曤炒臧赌 瓿店皽霅� 鞓堨爼鞛呺媹雼�. 鞚� 韺岉姼雱堨嫮鞚� AutoIVF鞚� 鞁滌灔 歆勳瀰鞚� 臧赌靻嶍檾頃橁碃 鞛愲彊頇� 氚� 順侅嫚鞚� 韱淀暣 靸濎嫕 旃橂 鞝戧芳靹膘潉 頇曤寑頃橂姅 雿� 氇╈爜鞚� 鞛堨姷雼堧嫟.
Vitrolife Group (VTRLY) a annonc茅 un investissement strat茅gique dans AutoIVF, devenant son principal investisseur. AutoIVF d茅veloppe 翱惫补搁别补诲测鈩�, un syst猫me automatis茅 qui simplifie la collecte et la pr茅paration des ovocytes lors des proc茅dures de FIV. Cette technologie vise 脿 am茅liorer les services de fertilit茅 et 脿 permettre la collecte d鈥檕vocytes en dehors des laboratoires traditionnels de FIV.
Cet investissement s鈥檌nscrit dans la strat茅gie de Vitrolife de d茅velopper une plateforme compl猫te reliant produits et services tout au long du processus de FIV. L鈥檌mpact financier est qualifi茅 de minimal, avec plus de d茅tails qui seront communiqu茅s lors des r茅sultats du deuxi猫me trimestre. Ce partenariat vise 脿 acc茅l茅rer la mise sur le march茅 d鈥橝utoIVF et 脿 茅tendre l鈥檃cc猫s aux soins de fertilit茅 gr芒ce 脿 l鈥檃utomatisation et 脿 l鈥檌nnovation.
Vitrolife Group (VTRLY) hat eine strategische Investition in AutoIVF bekanntgegeben und ist damit Hauptinvestor geworden. AutoIVF entwickelt 翱惫补搁别补诲测鈩�, ein automatisiertes System, das die Eizellentnahme und -vorbereitung bei IVF-Verfahren vereinfacht. Die Technologie zielt darauf ab, die Fertilit盲tsdienste zu verbessern und die Eizellentnahme au脽erhalb traditioneller IVF-Labore zu erm枚glichen.
Diese Investition passt zur Strategie von Vitrolife, eine durchg盲ngige Plattform zu entwickeln, die Produkte und Dienstleistungen im IVF-Ablauf miteinander verbindet. Die finanziellen Auswirkungen werden als gering beschrieben, weitere Details werden im Rahmen der Quartalsergebnisse im zweiten Quartal bekanntgegeben. Die Partnerschaft soll den Markteintritt von AutoIVF beschleunigen und den Zugang zur Fertilit盲tsversorgung durch Automatisierung und Innovation erweitern.
- Strategic investment aligns with corporate strategy to improve IVF accessibility and affordability
- Investment strengthens Vitrolife's position in automated IVF solutions
- Partnership could enable expansion of IVF services beyond traditional laboratory settings
- Financial impact described as minimal, suggesting limited near-term revenue contribution
- Early-stage investment carries inherent technology and market adoption risks
AutoIVF, is an early-stage MedTech company with the aim to make IVF more accessible, affordable and efficient. Its technology, 翱惫补搁别补诲测鈩�, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation, enabling high-quality fertility services in the current IVF process and also supports decentralising the egg retrieval process outside traditional IVF laboratory settings.听
''This investment marks another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care," says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group.
Ravi Kapur, CEO of AutoIVF, shares, "With this new investment and partnership, we are excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem."
Financial impact is minimal, more details will be disclosed during the Q2 earnings release.
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
Contact:
Amelie Wilson, Investor Relations, [email protected]听
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision
The following files are available for download:
| Vitrolife AB (publ) becomes lead investor in AutoIVF |
View original content:
SOURCE Vitrolife AB
FAQ
What is the purpose of Vitrolife's (VTRLY) investment in AutoIVF?
What is AutoIVF's 翱惫补搁别补诲测鈩� technology?
What is the financial impact of Vitrolife's investment in AutoIVF?
How will this investment benefit Vitrolife's (VTRLY) business strategy?
